2025-04-25 04:11:17
Latest Post
Prime Securities Ltd Q4 FY2025 net profit at Rs. 96 lakhs
Macrotech Developers Ltd consolidated Q4FY25 PAT at Rs. 921.7 crores
Accelya Solutions' Consolidated Income for Q3 at Rs. 1,367.55 Million
Insolation Energy Limited invests in rights issue of Insolation Green Energy Pvt Ltd
Minor fire incident in BHEL Bhopal
Stock Report
Parmax Pharma Ltd posts Rs. 4.59 lakhs loss in Q4FY22
Posted On : 2022-06-09 12:50:57( TIMEZONE : IST )
Parmax Pharma Ltd has reported Standalone financial results for the period ended March 31, 2022.
Financial Results (Q4 FY2022) - QoQ Comparison
The company has reported total income of Rs. 7.1047 crores during the period ended March 31, 2022 as compared to Rs. 2.8914 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs. -0.0459 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs. -0.5180 crores for the period ended December 31, 2021.
The company has reported EPS of Rs. -0.12 for the period ended March 31, 2022 as compared to Rs. -1.38 for the period ended December 31, 2021.
| Financials | Q4 FY2022 | Q3 FY2022 | % Change |
| Total Income | ₹ 7.1047 crs | ₹2.8914 crs |  145.72% |
| Net Profit | ₹-0.0459 crs | ₹-0.5180 crs |  91.14% |
| EPS | ₹-0.12 | ₹-1.38 | 91.30% |
Financial Results (Q4 FY2022) - YoY Comparison
The company has reported total income of Rs. 7.1047 crores during the period ended March 31, 2022 as compared to Rs.7.4147 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.-0.0459 crores for the period ended March 31, 2022 as against net profit / (loss) of Rs.-0.2967 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.-0.12 for the period ended March 31, 2022 as compared to Rs.-0.79 for the period ended March 31, 2021.
| Financials | Q4 FY2022 | Q4 FY2021 | % Change |
| Total Income | ₹ 7.1047 crs | ₹7.4147 crs |  -4.18% |
| Net Profit | ₹-0.0459 crs | ₹-0.2967 crs | 84.53% |
| EPS | ₹-0.12 | ₹-0.79 | 84.81% |
Financial Results (Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.18.3139 crores during the Financial Year ended March 31, 2022 as compared to Rs.26.2934 crores during the Financial Year ended March 31, 2021.
The company has posted net profit / (loss) of Rs.0.1415 crores for the Financial Year ended March 31, 2022 as against net profit / (loss) of Rs.0.7544 crores for the Financial Year ended March 31, 2021.
The company has reported EPS of Rs.0.38 for the Financial Year ended March 31, 2022 as compared to Rs.2.02 for the Financial Year ended March 31, 2021.
| Financials | Year Ended FY2022 | Year Ended FY2021 | % Change |
| Total Income | ₹18.3139 crs | ₹26.2934 crs | -30.35% |
| Net Profit | ₹0.1415 crs | ₹0.7544 crs | -81.24% |
| EPS | ₹0.38 | ₹2.02 | -81.19% |
Shares of Parmax Pharma Ltd was last trading in BSE at Rs. 38.80 as compared to the previous close of Rs. 39.15. The total number of shares traded during the day was 678 in over 20 trades.
The stock hit an intraday high of Rs. 39.65 and intraday low of 35.05. The net turnover during the day was Rs. 24576.00.
